Coated-wire-in-tube processing of bismuth-2223 superconductors

A coated-wire-in-tube (CWIT) process greatly increases the silver/superconductor interface area in silver-sheathed Bi-2223 superconductors. When the performance of CWIT samples is compared to that of conventional monofilaments made with the same powder, critical current density increases significantly with increased silver/superconductor interface area. Benefits of increasing the silver/superconductor interface area are realized only when there is good continuity of the coated wires, and this requires a mechanical deformation sequence to preserve good continuity of the wires

Effect of lead content on phase evolution and microstructural development in Ag-clad Bi-2223 composite conductors

A two powder process was used to prepare silver-sheathed monofilamentary Bi{sub 1.8}Pb{sub x}Sr{sub 1.98}Ca{sub 1.97}Cu{sub 3.08}O{sub y} (Bi-2223) tapes with varying lead contents, x, from 0.2 to 0.5. The resulting tapes were subjected to thermomechanical processing and then characterized by x-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive x-ray analysis (EDX). Layered phase texture was accessed using image analysis software on scanned SEM micrographs. Transport currents were measured at 77 K and zero field by the four-probe method. It was found that tapes with low lead content (X = 0.2 and 0.25) showed incomplete conversion to Bi-2223, had small grain size and poor c-axis texture. Tapes having higher lead content (x = 0.4 and 0.5) also showed incomplete conversion and the presence of lead-rich secondary phases. Tapes with lead content x = 0.3 and 0.35 showed complete conversion to Bi-2223, and had the least amount of secondary phases, the best c-axis texture, and the highest transport current (j{sub c}). The carbon content of the precursor powder also had a strong influence on secondary-phase chemistry

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Ultrafast laser micro-nano structuring of transparent materials with high aspect ratio

Ultrafast lasers are ideal tools to process transparent materials because they spatially confine the deposition of laser energy within the material's bulk via nonlinear photoionization processes. Nonlinear propagation and filamentation were initially regarded as deleterious effects. But in the last decade, they turned out to be benefits to control energy deposition over long distances. These effects create very high aspect ratio structures which have found a number of important applications, particularly for glass separation with non-ablative techniques. This chapter reviews the developments of in-volume ultrafast laser processing of transparent materials. We discuss the basic physics of the processes, characterization means, filamentation of Gaussian and Bessel beams and provide an overview of present applications

Single-mode tellurite glass holey fiber with extremely large mode area for infrared nonlinear applications

We report the fabrication of a large mode area tellurite holey fiber from an extruded perform, with a mode area of 3000µm2. Robust single-mode guidance at 1.55µm was confirmed by both optical measurement and numerical simulation. The propagation loss was measured as 2.9dB/m at 1.55µm. A broad and flat supercontinuum from 0.9 to 2.5µm with 6mW output was obtained with a 9cm length of this fiber